

Genetype Business Unit – New Product Sales Recorded

Highlights

- ✓ **First commercial sales have now been recorded under Rhythm’s leadership since restoring Genetype’s commercial capabilities in February.**
- ✓ **Initial sales in 2025 were patient cases being processed assumed by Rhythm during the Genetype acquisition, whereas Rhythm has now generated new sales.**
- ✓ **Commercial B2B sales of the full portfolio of geneTypeTM products are expected to grow throughout the year, aided by a reinvigorated team and process.**
- ✓ **Strategic growth will be driven by focussing upon enterprise market segments, with geographic expansion.**

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) is pleased to report that the Genetype business (acquired 24 December 2024), has recorded first commercial sales under Rhythm’s ownership.

Rhythm is confidently forecasting an attractive sales growth profile for geneTypeTM products over the foreseeable future, driven by:

- A list of potential enterprise customers.
- Support from influential Key Opinion Leaders (KOLs).
- High quality clinical evidence including a library of peer reviewed publications.
- A rich roadmap of potential product improvements.
- Opportunity for geographic expansion.

Rhythm Managing Director and Chief Executive Officer, Dr David Atkins commented “It is most pleasing to have crossed this threshold, with Rhythm from here on being able to record commercial sales revenues. Although non-material, at present, we are confident that the suite of products will support commercial revenue growth over ensuing periods. It is a credit to the dedication of the Rhythm and ongoing Genetype team to have re-established commercial activities so soon. With growing revenues expected from the geneTypeTM product portfolio, we look forward to adding to this with ColoSTAT[®] commercial revenues in the next financial year.”

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

Directors

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.